Search Results - "Werner, T.L."

A randomized trial comparing electrosurgical bipolar vessel sealing versus standard surgical resection at time of abdominal omentectomy for women with ovarian, primary peritoneal, or fallopian tube cancer by Soisson, A.P, Werner, T.L, Dodson, M.K

Get full text

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study by Sill, M, Tenney, M.E, Darus, C.J, Griffin, D, Werner, T.L, Waggoner, S.E, Behrens, R.J

Get full text

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study by Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., Dang, C.

“…Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac…”
Get full text

Endometrial cancers are successfully targeted with a new pan-tyrosine kinase inhibitor in an orthotopic mouse model by Janát-Amsbury, M.M., Taurin, S., Yang, C.H., Reyes, M., Coombs, D., Jarboe, E.A., Werner, T.L., Peterson, C.M.

Get full text

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) by Coleman, R.L., Fleming, G.F., Brady, M.F., Swisher, E., Steffensen, K.D., Friedlander, M., Okamoto, A., Moore, K., Ben-Baruch, N., Werner, T.L., Oaknin, A., Nam, J.-H., Leath, C.A., Nicum, S., Cella, D., Sullivan, D.M., Ansell, P.J., Dinh, M., Aghajanian, C., Bookman, M.A.

Get full text

LBA3 - VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) by Coleman, R.L., Fleming, G.F., Brady, M.F., Swisher, E., Steffensen, K.D., Friedlander, M., Okamoto, A., Moore, K., Ben-Baruch, N., Werner, T.L., Oaknin, A., Nam, J.-H., Leath, C.A., Nicum, S., Cella, D., Sullivan, D.M., Ansell, P.J., Dinh, M., Aghajanian, C., Bookman, M.A.

“…This phase III randomized placebo (PL) controlled multinational trial evaluated whether progression-free survival (PFS) is increased when V is added to…”
Get full text

442O - PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826) by Munster, P., van der Noll, R., Voest, E., Specht, J., Werner, T.L., Dees, E.C., Tan, A.R., Daud, A., Schellens, J., Lolkema, M.P., Griffin, M., Agarwal, N., Falchook, G.S., Kleha, J.F., Durante, M., Smith, D.A., Adams, L., Greshock, J., Morris, S.R., Kurzrock, R.

“…GSK458 is an oral, potent inhibitor of PI3K (α, β, γ, δ), mTORC1, and mTORC2. Cell lines with activation of the PI3K pathway are more likely to be sensitive to…”
Get full text

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826) by Munster, P., van der Noll, R., Voest, E., Specht, J., Werner, T.L., Dees, E.C., Tan, A.R., Daud, A., Schellens, J., Lolkema, M.P., Griffin, M., Agarwal, N., Falchook, G.S., Kleha, J.F., Durante, M., Smith, D.A., Adams, L., Greshock, J., Morris, S.R., Kurzrock, R.

Get full text